Circio and Lonza Sign Research Agreement to Test Circular mRNA Tech
Circio to evaluate its circVec mRNA platform using Lonza’s protein expression system.
Circio Holding ASA, a Norway-based biotech innovator, announced a new research evaluation agreement between its Swedish subsidiary Circio AB and global CDMO leader Lonza. The partnership allows Circio to assess its proprietary circVec circular mRNA expression technology using Lonza’s advanced transient protein expression platform—marking a key step toward scaling next-gen mRNA therapeutics.
The collaboration gives Circio access to Lonza’s expertise in protein production as it continues developing cutting-edge circular mRNA tools for nucleic acid-based medicine. According to the company, further updates will be provided as the evaluation progresses, potentially paving the way for deeper collaboration in therapeutic manufacturing.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®
Discussion